Key result
The crystal structure of the hepatitis C virus NS2-3 protease catalytic domain reveals a unique composite active site that offers a new opportunity for antiviral drug design.
The crystal structure of the HCV NS2-3 protease reveals a unique composite active site that may inform antiviral drug design.
Answers are grounded in this paper and cite their sources.
May guide HCV antiviral design; leaves open clinical translation pending validation.
The crystal structure of the catalytic domain of hepatitis C virus NS2-3 protease reveals a unique composite active site. Information from the structure may lead to the design of new antiviral drugs to control liver disease.
No takes yet. Share an insight, caveat, or question.
Suo et al. (2007) studied this question. The crystal structure of the hepatitis C virus NS2-3 protease catalytic domain reveals a unique composite active site that offers a new opportunity for antiviral drug design.
Synapse has enriched 10 related papers. Consider them for comparative context: